Novartis recognizes the public health need for better usage of vaccines and medications in developing countries. Novartis is working closely with developing countries and international health agencies to find sustainable solutions for effective distribution of important medicines for illnesses such as malaria, meningitis, leprosy and tuberculosis. In November 2009 Celtura was approved for make use of in both Germany and Switzerland, and Novartis is looking for approval in several other countries also. On September 29 Focetria was approved by the European Union, 2009, for use in every 27 member claims of europe, plus, by expansion, in Iceland, Norway and Liechtenstein through the European Economic Area Agreement.With FDA approval, XIENCE PRIME is currently obtainable in the U.S., Europe, the center East and most of Asia. XIENCE PRIME is indicated for enhancing coronary artery luminal diameter in individuals with symptomatic heart disease due to de novo native coronary artery lesions with reference vessel diameters of greater than or equal to 2.25 mm to less than or equal to 4.25 mm. Abbott’s market-leading XIENCE V medication eluting stent can be marketed in the U.S., Europe, Japan and additional international marketplaces. XIENCE V can be indicated for enhancing coronary luminal size in sufferers with symptomatic cardiovascular disease due to de novo indigenous coronary artery lesions with reference vessel diameters of 2.25 mm to 4.25 mm.